9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

ATREUS – Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)

Estimated reading time: < 1 min

Condition

Malignant Pleural Mesothelioma

Estimated Enrollment: 141

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: IRFMN-MPM-6077|2011-006330-16

Study First Received: July 16, 2014

Last Updated: August 30, 2016

Estimated Primary Completion Date: October 2016

Primary Outcome Measures:

Progression Free Survival – PFS12w|Progression Free Survival (PFS)|Overall survival (OS)|Objective response rate|Trabectedin tolerability and safety|Pain Intensity (PI)|Pain type and characteristics|Antalgic treatments|microRNA (miRs) profile|High Mobility Group B1 (HMGB1) protein assessment|Blood Macrophages analysis

Sponsors and Collaborators:

Mario Negri Institute for Pharmacological Research|PharmaMar

Result Received: No Study Results Posted

Website Link: https://ClinicalTrials.gov/show/NCT02194231

Was this article helpful?
Views: 57